Mylan Estimated ABOVE Consensus and 4 Stock Analyses to Notice
Redwood Trust Inc. (NYSE:RWT): FBR Capital thinks that the market is giving Redwood Trust’s conduit business too much credit since it only contributed 2c of the company’s core EPS of 20c during Q2. The firm believes that the stock is way ahead of itself currently, and it reiterates an Underperform rating on the stock. However, FBR increased its price target to $12 from $10 on the stock.
Don’t Miss: Toyota’s Plan for the Future.
Mylan, Inc. (NASDAQ:MYL) Q3 estimates have been increased by Canaccord to above consensus because of Epi-Pen strength and Gx Actos. The firm left its 2013 estimates unchanged because of low visibility and mentions that a take-out is not likely. Shares have a Hold rating.
Integra LifeSciences Holdings Corporation (NASDAQ:IART): After meeting with Integra’s CEO, Oppenheimer believes that the stock will increase into the company’s analyst day on October 24, when it is expected to announce more details about its cost saving plans. The firm predicts that the company’s operating margin will rise, and it reiterated an Outperform rating and increased its target to $46 from $42 on the stock.
Endologix Inc. (NASDAQ:ELGX): Oppenheimer thinks that an insider’s sale of Endologix’s stock, along with a coming intellectual property trial, have added weight to Endologix’s shares. However, the firm does not believe that either of these events are important, and the firm keeps an Outperform rating on the shares.
Halliburton Company (NYSE:HAL): According to FBR Capital, Halliburton’s share price does not reflect potential margin upside from lower guar prices next year and international share gains. Shares have an Outperform rating.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>